Designing a novel (R)- ω-transaminase for asymmetric synthesis of sitagliptin intermediate via motif swapping and semi-rational design
This study underscores a useful evolution strategy of engineering biocatalysts to confer new properties and functions on enzymes for synthesizing high-value drug intermediates.PMID:37820904 | DOI:10.1016/j.ijbiomac.2023.127348 (Source: International Journal of Biological Macromolecules)
Source: International Journal of Biological Macromolecules - October 11, 2023 Category: Biochemistry Authors: Fang-Ying Zhu Meng-Yu Huang Ken Zheng Xiao-Jian Zhang Xue Cai Liang-Gang Huang Zhi-Qiang Liu Yu-Guo Zheng Source Type: research
Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
Conclusion: Our results demonstrate there is a considerable amount of comparative RWE for apixaban, rivaroxaban, and etanercept but limited comparative RWE for the other drugs set to undergo CMS price negotiations in 2026; additionally, our findings set up a number of next steps (e.g., risk of bias assessments) for further exploration of the available evidence base. Overall, CMS and manufacturers should consider proactively generating high-quality comparative RWE studies in the Medicare population to ensure that future price negotiations are based on robust evidence.PMID:37815792 | DOI:10.57264/cer-2023-0125 (Source: Journ...
Source: Journal of Comparative Effectiveness Research - October 10, 2023 Category: General Medicine Authors: Ashley Jaksa Patrick J Arena Nicolle Gatto Source Type: research
HHS Announces First 10 Drugs Up for Price Negotiation
The US Department of Health and Human Services (HHS), through the Centers for Medicare& Medicaid Services, recently selected the 10 drugs for which they will begin negotiating prices as part of the Inflation Reduction Act. The medications are Eliquis; Enbrel; Entresto; Farxiga; Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen, NovoLog PenFill; Imbruvica; Januvia; Jardiance; Stelara; and Xarelto. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - September 13, 2023 Category: General Medicine Source Type: research
Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial
CONCLUSIONS: Empagliflozin was superior to sitagliptin in relation to glycemic control, weight, and systolic/diastolic blood pressure reduction.PMID:37606137 | DOI:10.26355/eurrev_202308_33300 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - August 22, 2023 Category: Drugs & Pharmacology Authors: H G Zakaraia H F Salem M A A Mostafa A M Ali H Rabea Source Type: research
Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial
CONCLUSIONS: Empagliflozin was superior to sitagliptin in relation to glycemic control, weight, and systolic/diastolic blood pressure reduction.PMID:37606137 | DOI:10.26355/eurrev_202308_33300 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - August 22, 2023 Category: Drugs & Pharmacology Authors: H G Zakaraia H F Salem M A A Mostafa A M Ali H Rabea Source Type: research
Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial
CONCLUSIONS: Empagliflozin was superior to sitagliptin in relation to glycemic control, weight, and systolic/diastolic blood pressure reduction.PMID:37606137 | DOI:10.26355/eurrev_202308_33300 (Source: Molecular Medicine)
Source: Molecular Medicine - August 22, 2023 Category: Molecular Biology Authors: H G Zakaraia H F Salem M A A Mostafa A M Ali H Rabea Source Type: research
Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial
CONCLUSIONS: Empagliflozin was superior to sitagliptin in relation to glycemic control, weight, and systolic/diastolic blood pressure reduction.PMID:37606137 | DOI:10.26355/eurrev_202308_33300 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - August 22, 2023 Category: Drugs & Pharmacology Authors: H G Zakaraia H F Salem M A A Mostafa A M Ali H Rabea Source Type: research
Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial
CONCLUSIONS: Empagliflozin was superior to sitagliptin in relation to glycemic control, weight, and systolic/diastolic blood pressure reduction.PMID:37606137 | DOI:10.26355/eurrev_202308_33300 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - August 22, 2023 Category: Drugs & Pharmacology Authors: H G Zakaraia H F Salem M A A Mostafa A M Ali H Rabea Source Type: research
